Jam

Axcap Ventures (CSE: AXCP) acquired Carlyle Commodities’ Newton Gold Project in British Columbia for up to $8 million, gaining full ownership of the 23,003-hectare property with an inferred resource of 843,000 oz gold and 4.5 million oz silver. The deal includes $500,000 cash, 3.75 million shares, and warrants for Carlyle, plus performance-based incentives tied to resource expansion and feasibility milestones. A 2% net smelter royalty includes an option for Axcap to buy back half for $2 million. The acquisition positions Axcap to explore the underexplored Cariboo region amid high gold prices, though challenges include low 0.64 g/t grades and potential shareholder dilution. Initial drilling results are expected in late 2025.

TotalEnergies launched oil production from its Mero-4 phase in Brazil’s pre-salt Santos Basin, bolstering its low-carbon strategy. The offshore project, linked to the 180,000 b/d Alexandre de Gusmão FPSO, employs emissions-reduction technologies like gas reinjection. Combined with existing units, Mero’s total output reaches 770,000 b/d. TotalEnergies’ stake is expected to deliver 100,000 boe/d. Operated by the Libra Consortium (Petrobras, TotalEnergies, Shell, CNPC, CNOOC, and Pré-Sal Petróleo), the project aligns with the company’s 3% annual production growth target by 2030. TotalEnergies also emphasized Brazil’s role in its renewables expansion, including a 12 GW solar/wind joint venture, balancing hydrocarbon growth with sustainability goals.

Innovent Biologics’ dual GCG/GLP-1 agonist mazdutide demonstrated significant weight loss (14.84% vs. 0.47% placebo) in a Phase 3 trial (GLORY-1) with 610 Chinese adults with obesity over 48 weeks, published in *NEJM*. Over 50% achieved ≥15% weight reduction, alongside improved cardiovascular and liver health. Safety aligned with GLP-1 therapies, with transient gastrointestinal effects. This marks the first NEJM-published metabolic therapy trial from China, signaling the nation’s rise in drug innovation. Experts emphasized mazdutide’s potential in addressing China’s obesity crisis under “Healthy China 2030.” Partnerships with Eli Lilly and ongoing trials aim to expand its use in metabolic diseases.

Elektros Inc. (OTC: ELEK) announced a major lithium discovery in Sierra Leone, with grades exceeding commercial thresholds, positioning it among West Africa’s largest undeveloped deposits. The find aligns with projections of 42-fold lithium demand growth by 2040, offering potential to diversify EV supply chains amid automakers’ push for ethical sourcing. Despite Sierra Leone’s challenging business environment and Elektros’ microcap status ($12M valuation), proximity to ports and low impurity levels present advantages. Risks include unproven feasibility and infrastructure gaps. Tesla’s recent Africa-focused lithium strategy and regional patent filings hint at synergies. Success hinges on partnerships, testing, and navigating local regulations to transform the deposit into a supply chain asset.

Vail Resorts adds Austria’s Sölden to the Epic Pass for 2025/26, expanding European access. The Tyrolean resort offers 89 miles of glacier terrain, cultural attractions like the 007 ELEMENTS exhibit, and hosts premier events. Priced at $1,051 (adults) until May 26, the pass includes five days at Sölden, discounts, and access to 34 resorts across 10 European regions. New lifts will enhance glacier access next season. The partnership aligns with Vail’s 2030 net-zero goal and Europe’s travel rebound. Prices rise post-deadline, urging skiers to secure the year’s lowest rates for premium alpine destinations.

Elektros Inc. (OTC: ELEK) announced a major lithium discovery in Sierra Leone, potentially among West Africa’s largest deposits, with grades exceeding initial estimates. CEO Shlomo Bleier called it “transformative,” aligning with surging EV battery demand forecasted to grow 42-fold by 2040. The find could diversify global lithium supply dominated by Australia, Chile, and China, easing EV production bottlenecks. Despite a 23% pre-market stock surge, challenges include 3-5 years of pre-production studies, Sierra Leone’s governance risks, and volatile lithium prices. Elektros plans AI-driven exploration to expedite development, mirroring Rio Tinto’s cost-reduction strategies. The project highlights West Africa’s role in ethical, geopolitically balanced supply chains.

Travelzoo launched new **Club Offers**, providing members exclusive deals on curated global travel experiences. Highlights include a 5-night Lisbon package with flights from $799, 73% off Budapest’s Kimpton BEM hotel, Toronto boutique stays at 65% savings, and a $999 Tuscan villa retreat with meals. Limited-time offers feature Canadian destinations like Vancouver Island lodges and discounted Toronto Argonauts tickets. As a trusted platform with 30 million members, Travelzoo guarantees human-vetted deals through partnerships with premium suppliers. Membership remains free, with new weekly offers added through summer.

Travelzoo (NASDAQ: TZOO) has launched exclusive “Club Offers” for its 30 million members, featuring curated luxury travel experiences across Europe at up to 72% discounts. Highlights include a €199 Swiss Alps retreat, Tuscan vineyard stays from €379, Parisian boutique hotels at 75% off, and a UNESCO-adjacent Budapest property for €99. These deals, vetted by industry experts, blend cultural immersion with significant savings, targeting affluent travelers seeking value and shareable experiences. The initiative aligns with global trends prioritizing meaningful travel, leveraging Travelzoo’s 25-year expertise and partnerships with 2,000 premium suppliers. Offers are time-sensitive and accessible via subscription on travelzoo.com.

Argo Living Soils Corp. (CSE: ARGO) granted 1.8 million incentive stock options at $0.65/share to executives, directors, and consultants, immediately vested with a 2028 expiration. The move aligns stakeholders with the company’s expansion in graphene-enhanced concrete and organic fertilizers, despite potential 4.7% shareholder dilution. A four-month trading lockup aims to stabilize stock liquidity while analysts highlight accelerated vesting as a strategic push for near-term milestones. With shares trading below the strike price at $0.58, the package signals confidence in upcoming commercialization of eco-technologies, aligning with global sustainability initiatives like the U.S. Inflation Reduction Act.

Mineralys Therapeutics’ lorundrostat, a novel aldosterone synthase inhibitor, demonstrated strong Phase 3 results in treating resistant hypertension across 1,000+ patients. The trial showed sustained systolic reductions of 19.0 mmHg (11.7 mmHg vs placebo) at 12 weeks and a favorable safety profile with 0.1% serious adverse events. Exceeding FDA efficacy benchmarks, the therapy achieved dual Phase 3 validation and potentially reduces cardiovascular risk by 20-40%. With patent protection through 2041 and a projected $10B+ market opportunity, Mineralys plans Q1 2026 regulatory submission. The company’s $1.2B market cap signals growth potential amid rising global demand for precision hypertension treatments.